We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » Patient Death Prompts Pause in Atara’s Mesothelioma CAR-T Cell Study
Patient Death Prompts Pause in Atara’s Mesothelioma CAR-T Cell Study
A patient death has prompted Atara Biotherapeutics to issue a voluntary hold on patient recruitment into its potentially groundbreaking phase 1 trial of the CAR-T cell therapy ATA2271 for pleural mesothelioma, an untreatable cancer.